We therefore first compared changes in the transcriptomes of two HER2+ BC cell lines (SBKR3 and BT474) after treatment with the HER2/EGFR inhibitor lapatinib or the CDK7 inhibitor THZ1. Here, EGFR is linked to breast cancer.